Roivant Sciences ROIV Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Free cash flow margin | -22,499.4%-12,970pp | -9,529.9%-2,274pp | -7,255.4%+503pp | -7,758%-2,026pp | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×— | |
| Liquidity | |||||
| Current ratio | 123.3×+13.6× | 109.7×+44.5× | 65.2×+38.3× | 27×-17.2× | |
| Quick ratio | 123.3×+13.7× | 109.6×+44.5× | 65.1×+38.1× | 27×-17.2× | |
| Cash ratio | 7.2×-20.8× | 28×-11.2× | 39.3×+13.8× | 25.5×-17.5× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0.1×-1.1× | 1.2×-0.5× | 1.7×+1.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×-0.5× | 0.6×-0.2× | 0.8×+0.4× | |
| Per Share | |||||
| Book value per share | $25.45-7.8% | $27.60+64.1% | $16.82+154% | $6.61-39.8% | |
| Valuation | |||||
| Market capitalization | $53.09B+65.5% | $32.08B-6.2% | $34.21B+108% | $16.43B-30.4% | |
| Enterprise value | $51.8B+94.0% | $26.7B+0.9% | $26.47B+129% | $11.56B-27.2% | |
| Price / sales | 4,379.9×+3,406× | 974.1×+220× | 754.1×+357× | 397.5×-155× | |
| Price / book | 12.1×+5.8× | 6.3×-14.6× | 20.9×+6.1× | 14.8×+1.9× | |
| EV / sales | 4,222.4×+3,397× | 825.7×+257× | 568.6×+282× | 286.5×-91.2× | |
| Free cash flow yield | -27.4%+11.7pp | -39.1%-0.4pp | -38.8%+58.1pp | -96.9%-48.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Roivant Sciences's ratios come from?
- Every ratio is computed from Roivant Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
